Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Accenture
Dow
Fish and Richardson
Express Scripts
Merck
Moodys
Colorcon
Cerilliant

Generated: December 12, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VALSARTAN

« Back to Dashboard

Clinical Trials for Valsartan

Trial ID Title Status Sponsor Phase Summary
NCT00034840 Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose Completed Bayer Phase 4 The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00034840 Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose Completed GlaxoSmithKline Phase 4 The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00034840 Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose Completed Boehringer Ingelheim Phase 4 The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00089518 Optimal Treatment for Kidney Disease in HIV Infected Adults Withdrawn National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 The angiotensin receptor blocker (ARB) valsartan is a drug commonly used to treat high blood pressure. Valsartan may also help slow down the progression of kidney disease in HIV infected people. The purpose of this study is to compare valsartan and antiretroviral therapy (ART) to ART alone in slowing kidney disease progression in people with HIV.
NCT00097786 Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications Completed Novartis Pharmaceuticals Phase 3 This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular complications. People in this study cannot have frank diabetes but are considered "borderline" based on blood tests. People in the study take none, one or both of the drugs and do not know which one(s) they are taking.
NCT00129233 Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance Completed Nagoya University Phase 4 Various guidelines recommended angiotensin converting enzyme (ACE) inhibitors or angiotensin Ⅱ receptor-1 blockers (ARBs) for hypertensive patients with diabetes on the basis of the cardiac- and reno-protective effects of these drugs. However, these recommendations could not be extrapolated to Japanese patients, because Japan has been known as a country with a low incidence of coronary artery disease and a high incidence of cerebrovascular disease. Furthermore, calcium channel blockers (CCBs) also were protective against renal function as well as ACE inhibitors in Japanese diabetic hypertensive patients. This study will test whether ARBs or CCBs are superior in treating Japanese diabetic hypertensive patients.
NCT00130156 Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension Completed Eisai Co., Ltd. Phase 4 The purpose of this study is to investigate the efficacy and safety of Bunazosin with Valsartin compared to Doxazosin with Valsartin for patients with mild to moderate essential hypertension accompanied by metabolic syndrome.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Valsartan

Condition Name

Condition Name for Valsartan
Intervention Trials
Hypertension 148
Healthy 17
Essential Hypertension 12
Heart Failure 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Valsartan
Intervention Trials
Hypertension 152
Heart Failure 30
Diabetes Mellitus 22
Kidney Diseases 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Valsartan

Trials by Country

Trials by Country for Valsartan
Location Trials
United States 426
Italy 134
Korea, Republic of 68
China 51
Germany 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Valsartan
Location Trials
New Jersey 41
California 18
Texas 18
Pennsylvania 17
Illinois 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Valsartan

Clinical Trial Phase

Clinical Trial Phase for Valsartan
Clinical Trial Phase Trials
Phase 4 123
Phase 3 86
Phase 2/Phase 3 4
[disabled in preview] 71
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Valsartan
Clinical Trial Phase Trials
Completed 194
Recruiting 27
Not yet recruiting 22
[disabled in preview] 40
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Valsartan

Sponsor Name

Sponsor Name for Valsartan
Sponsor Trials
Novartis 90
Novartis Pharmaceuticals 43
Boehringer Ingelheim 7
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Valsartan
Sponsor Trials
Industry 204
Other 171
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Queensland Health
Federal Trade Commission
Moodys
Cerilliant
Argus Health
Fuji
Chinese Patent Office
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.